Scarica l'app Stockscreener
1.245
5.51%
0.065
Alx Oncology Holdings Inc Borsa (ALXO) Ultime notizie
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - Yahoo Finance
After-Hours Gainers: ALXO, GMED, ACRV, And Biotech Peers Rally On Trial Data And Earnings Updates - RTTNews
Meme Stocks: Will ALX Oncology Holdings Inc stock deliver consistent dividends2025 Valuation Update & Weekly Market Pulse Updates - moha.gov.vn
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Short Interest in ALX Oncology Holdings Inc. (NASDAQ:ALXO) Expands By 32.0% - Defense World
ALXOAmended Statement of Beneficial Ownership (3/a) - ADVFN
ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights - ADVFN
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update - ADVFN
ALX Oncology (NASDAQ:ALXO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
How geopolitical tensions affect ALX Oncology Holdings Inc. stockWeekly Trade Summary & Breakout Confirmation Trade Signals - DonanımHaber
Aug PostEarnings: What technical charts say about ALX Oncology Holdings Inc. stock2025 Market WrapUp & Free Expert Verified Stock Movement Alerts - DonanımHaber
What momentum indicators show for ALX Oncology Holdings Inc. stockMarket Risk Summary & AI Driven Price Forecasts - Улправда
Alx Oncology: A Study in Contrasting Market Sentiment - AD HOC NEWS
ALX Oncology (NASDAQ:ALXO) Lowered to “Sell” Rating by Wall Street Zen - Defense World
ALX Oncology (NASDAQ:ALXO) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Alx Oncology rallies on strong phase 2 data for lymphoma therapy - MSN
Alx Oncology stock soars after impressive lymphoma treatment results By Investing.com - Investing.com UK
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
ALX Oncology (Nasdaq:ALXO) Reports High Response Rates for Evorpacept Combo in Indolent B-cell NHL at ASH 2025 - Kalkine Media
ALXO: Promising Phase 2 Trial Results for Evorpacept in iNHL Tre - GuruFocus
Alx Oncology Holdings Inc. Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-Of-Care Treatment in Patients with Indolent B-Cell Non-Hodgkin Lymphoma, At Ashodgkinlymph - marketscreener.com
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting - Sahm
ALX Oncology (NASDAQ:ALXO) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
ALX Oncology (NASDAQ:ALXO) Stock Price Up 3.8%Here's Why - MarketBeat
Reviewing Harmony Biosciences (NASDAQ:HRMY) and ALX Oncology (NASDAQ:ALXO) - Defense World
Why ALX Oncology Holdings Inc. stock could benefit from AI revolutionMarket Growth Summary & High Accuracy Trade Signal Alerts - Newser
HER2-positive Gastric Cancer Clinical Trial Pipeline: Insights into a Growing Landscape with 20+ Companies Advancing Novel Treatments| DelveInsight - GlobeNewswire
How resilient is ALX Oncology Holdings Inc. stock in market downturnsMarket Trend Summary & Consistent Profit Trade Alerts - newser.com
Jefferies reiterates Buy rating on ALX Oncology stock, sees potential in cancer programs - Investing.com Canada
Can ALX Oncology Holdings Inc. hit a new high this month2025 Volatility Report & Daily Profit Maximizing Tips - newser.com
What analyst consensus says on ALX Oncology Holdings Inc. stockQuarterly Profit Summary & Consistent Growth Stock Picks - newser.com
Will ALX Oncology Holdings Inc. stock outperform Dow Jones index2025 Fundamental Recap & Accurate Entry/Exit Alerts - newser.com
Is ALX Oncology Holdings Inc. stock attractive for long term wealth buildingVolume Spike & Expert Curated Trade Setups - newser.com
Is ALX Oncology Holdings Inc. stock attractive for hedge fundsEntry Point & Consistent Growth Equity Picks - newser.com
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B - Markets Financial Content
ALXO: Two high-value oncology programs advance toward key 2025 data with strong financial support - TradingView
Published on: 2025-11-19 06:30:37 - newser.com
Published on: 2025-11-19 06:25:55 - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
Will ALX Oncology Holdings Inc. stock deliver long term returnsCEO Change & Entry Point Confirmation Signals - newser.com
Published on: 2025-11-18 23:37:11 - newser.com
5.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):